Welcome Welcome to the 29th Annual Sparkle of Hope Gala!
Congratulations to the 2025 Honoree Will Lewis Chairman and CEO of Insmed SPENCER SAVINGS BANK A PROUD SUPPORTER OF COMMUNITY HOPE
It is a privilege to welcome you to the 29th Annual Sparkle of Hope Gala. Community Hope is deeply grateful for your partnership and continued commitment to advancing our mission of restoring hope to individuals confronting mental illness, homelessness, and poverty. This evening, we gather to recognize the profound impact of Community Hope’s work and to honor the individuals whose
lives have been transformed through our programs. For 40 years, Community Hope has remained at the forefront of addressing the mental health needs of New Jersey’s most vulnerable residents. What began as a single supportive home for six individuals with serious mental illness has grown into the state’s largest nonprofit organization serving homeless veterans, veteran families, and adults facing mental health challenges. Across seven programs and 66 units of affordable housing, our multidisciplinary teams provide individualized support to help each person overcome the circumstances that led to their homelessness. Your continued generosity and engagement make this vital work possible. The Sparkle of Hope Gala was established in 1997 by Fred Hassan, former Chief Executive Officer of Schering-Plough, Pharmacia, and Upjohn, to align advances in pharmaceutical innovation with the delivery of community-based mental health services. Over the past 29 years, the Gala has raised more than $24 million in support of Community Hope, reflecting the sustained commitment and leadership of the life sciences community. As the demand for our services continues to grow, Community Hope remains steadfast in its dedication to providing high-quality care and permanent housing solutions for those in need. The growing national awareness surrounding mental health underscores the importance of our mission and the collective responsibility we share in addressing these challenges. On behalf of the Board of Directors, staff, and all those we serve, thank you for joining us this evening and for your enduring partnership. Your support ensures that Community Hope can continue to make a meaningful difference in the lives of countless individuals and families across New Jersey.
27 Financial Centers throughout New Jersey www.spencersavings.com
Community Hope Board of Directors John Iannetta President Laurie S. Becker Vice President Nicholas Lorusso Treasurer Todd A. Smith Secretary Eileen Griffith Eugene C Holloway, Esq. Jay H. Yarnis, DDS Emeritus Board Members
A Welcome from the Board President
Welcome to the 29th Annual Sparkle of Hope Gala. It is an honor to gather with you this evening for one of the most distinguished celebrations in our state—an event that brings together friends, colleagues, and champions of our mission to uplift lives through housing and healing.
Since joining the Board of Directors in 2017 and assuming the role of Board President in July 2022, I’ve witnessed firsthand the extraordinary impact of Community Hope. Our dedicated staff, led by CEO Carmine Deo and our Senior Leadership Team, work tirelessly to ensure that those we serve—veterans and individuals overcoming mental health challenges—have not only a roof over their heads, but a place to call home and a renewed sense of purpose. Thanks to your generosity, Community Hope provides housing, vital resources, and life- changing services to more than 1,200 individuals and families each year. You are helping us turn hope into homes, and homes into futures. Tonight, we are proud to honor Mr. Will Lewis, Chair and CEO of Insmed, with the 2025 Sparkle of Hope Award. His leadership in healthcare and unwavering commitment to helping others exemplify the spirit of this evening. We also celebrate Fred and Noreen Hassan, whose steadfast support since the Gala’s founding in 1997 has helped raise an astounding $24 million for Community Hope. Their loyalty and vision continue to guide our success. And we extend our deepest thanks to Brent Saunders, Chairman and CEO of Bausch + Lomb, whose leadership as Gala Chair has been instrumental in advancing our mission and expanding our reach. On behalf of the Board of Directors, our staff, and the thousands of lives you help transform, welcome to the Community Hope family. May tonight be a joyful and inspiring reminder of the power we have—together—to spark hope and build homes.
Paul Cocja Lucy C. Del Gaudio (Veteran Advisor) Fran DeSena Ann Mohamadi Belinda Perichi Brent Ragans John C. Stritehoff, USN (Veteran) Elias Tsepouridis David M. Wissert, Esq. Jen Zimmer Carmine V. Deo, MBA, MSW, LCSW Chief Executive Officer
John Iannetta, President Community Hope Board of Directors
Community Hope Impact Statement 2025
2025 Leadership Committee Members Leadership Committee Chairs Jen Zimmer Partner Insigniam Leadership Committee Founding Members
Richard Goldberg President and CEO R2 Associates, LLC
Thomas Kolaris Chief Commercial Officer BTG Specialty Pharmaceuticals
Anne St.Clair, CIMA, Director Senior Vice President, Private Wealth Advisor US Bank Private Wealth Management Leadership Committee Members Ann Mohamadi Managing Director, Pharmaceutical & Life Sciences Pricewaterhouse Coopers, LLP
Paul Boudreau Principal Owner, Paul Boudreau & Associates Paul Cocja Vice President & Head, Human Resources Novartis Pharmaceuticals Corporation Eric Dunn Senior Director, Training & Documentation, Otsuka Matt Fendler Systems Manager, BD Richard Goldberg President & CEO, R2 Associates LLC Adele M. Gulfo President and CEO Biopharma Strategies and Insights John Iannetta Founder/Principal, Commercial Operations Excellence dba CommOpEx Principal Consultant, TriRadial Solutions MariaGrace Iantosca Director, Cushman Wakefield Julie Kampf
Michael F. Lupton Branch Manager, First Vice President - Investments Wells Fargo Pamela A. Mader HR Leader, Horizon Blue Cross Blue Shield Stacia McDonough CEO, Neva Imports, LLC Robert Peluso President Parsippany Area Chamber of Commerce Belinda Perichi Vice President of Human Resources – Global Commercial (Retired), Allergan Bob Peterson Consultant, Insigniam Craig Robertson Partner, Accenture - Life Sciences Tony Rogers Managing Director, Wilmington Trust Melanie Ronsheim Senior Director, External Operations and Strategy GlaxoSmithKline Anne St.Clair, CIMA , Director Senior Vice President, Private Wealth Advisor US Bank Private Wealth Management
CEO and Chief Possibilities Officer JBK Associates International, Inc. Cezary Kuziemski Head of HR, US, Orion Innovation
COMMUNITY HOPE – 40 YEARS of Bringing Hope and Housing to People in Recovery
2011-2012
1985
1986
1987-1990
1991-1994
1997
1999-2000
2001
2003-2004
2006
2008 - 2011
1987 – 2nd Community residence established for 6 residents in Boonton
1986 - Project Hope purchases first house in Dover with $89,000 from NJ Division of Mental Health Services. With support of Congressman Rodney Frelinghuysen, this house is established as 1st Mental Health Transitional Housing Residence for 5 residents
1992 – We now serve 47 people. We are largest provider of long-term supportive housing in Morris County 1991 – Peter D’Souza joins Project Hope as Executive Director and Implements a philosophy of Consumer empower- ment, treating the whole person. Residents work towards self-sufficiency
2001– HUD Awarded the 1st of what will become 7 fully accessible properties
2003 – Community Hope conducts a major expan- sion of properties and is now serving nearly 100 individuals
2006 – Community Hope now serves 190 individuals in our residence recovery programs, quadrupling in 5 years.
2011 – Veterans Emergency Housing opens in Newark with 12 beds. We served more than 150 veterans in over 2 years
2011 – 1st Veteran served by our Supportive Services for Veteran Families Program (SSVF)
1997 - Project Hope changes its name and becomes Community Hope
2004 – CH awarded highest CARF accreditation
1985 – Project Hope is incorporated as private nonprofit with 9 member Board of Trustees
2012 – Eileen Griffith becomes President of the Board of Directors
2009 – The original 5 individuals from Berry Street opening still at CH!
2001 – 1st Flag Day 5K and Fun Walk
1999 – Mike Armstrong joins Community Hope as CEO
1990 – Project Hope now has 40 residents. Continuum of care established to consider individual needs of resident
1999 – Supportive Living Program is launched, the first in Morris County
2009 – NJAMHA selects CH as Outstanding Provider of the Year
2004 – Hope for Veter- ans Program (HVP) opens on the Lyons VA Campus with 70 beds. It is the largest transi- tional housing program in tri-state area for homeless veterans
2001 – Community Hope is now serving 57 individuals
2000 – Entered into CHAMP Partnerships Program agreements with CBH Care
2006 – Community Hope builds its first Affordable Housing residence from ground up
2008 – HVP Expanded to 95 beds
1994 – Project Hope develops a new Mission statement and its 1st strategic plan
2012 – Leadership Committee is formed as an ad-hoc committee of Community Hope’s Board of Directors
1997 – 1st Sparkle of Hope Gala
1986 – Debbie Miller is named Project Hope Execu- tive Director.
1985 – Carmela Lunt becomes President of the Board of Trustees
founded by Fred Hassan
COMMUNITY HOPE Mental Health Services Veteran Programs
2013 – Valley Brook Village Phase I opens with 62 units
2015 – Community Hope moves to its current office location at 959 Route 46 in Parsippany 2015 – Veterans Emergency Housing opens in Philadelphia with 20 beds serving 237 veterans in 2 years
2018 – Carmine Deo named Community Hope Executive Director
First VetFest held in Succasunna, NJ
2020 – Community Hope owns & main- tains 26 homes and operates an addi- tional 13
2022 – John Iannetta assumes responsibilities of President of the Board of Directors
2013 – Community Hope unveils new corporate logo and develops logo for Hope for Veterans
2025 – Community Hope celebrates its 40th Anniversary
2024 – Community Hope awarded new programs to provide nursing services to residents in our transitional housing and community support services mental health programs
2023 – Community Hope celebrates its 5 year partnership with Ferring Pharmaceuticals as a NYC Marathon Charity Partner.
35 Years
1985-2020
2021 – Community Hope hold its first virtual Sparkle of Hope Gala due to the ongoing COVID Pandemic
Community Hope Celebrates 35 years of providing the gift of hope to homeless veterans, veteran families and adults with mental illness
2019 - Valley Brook Village Phase II opens
2017 – Supportive Living Program transitions to CSS
2018 – Diana Lunt becomes President of the Board of Directors
2022 – Community Hope announces new rebranding
2013 – SSVF expands within NJ and into Northeastern PA and reaching nearly 1200 homeless and at-risk veterans
2025 – Community Hope awarded the Bringing Veterans Home Grant by the NJ Department of Community Affairs, a ground- breaking initiative to ensure no veteran in NJ has to endure the hardship of homelessness.
2017 – Brent Saunders assumes role of Sparkle of Hope Leadership Chair from Fred Hassan
2023 – Community Hope receives grant to establish a new case management program for veterans
2024 – Hope for Veterans Program celebrates 20th Anniversary
2014 – The Alfred J. Thomas Home for Veterans (AJT) opens in Partnership with Bergen County
2022 – Community Hope establishes the SSG Fox Veterans Suicide Prevention Program
2013
2013-2014
2015-2017
2018
2019
2020
2021-2022
2023
2024
2025
= Community Hope = Mental Health Services =Veteran Programs
Evening Program 29th Annual Sparkle of Hope Gala Evening Program 5:30-7:00pm Full Open Bar and Dinner Buffet 7:00pm Sparkle of Hope Reception Grand Legacy Ballroom Welcome Fred Hassan
Chairman, The Caret Group and Sparkle of Hope Founding Chair Carmine Deo Chief Executive Officer, Community Hope Video Presentation Sparkle of Hope Award Ceremony Brent Saunders Chairman and CEO, Bausch + Lomb and Sparkle of Hope Leadership Chair Introduction of Gala Chairs Introduction of Sparkle of Hope Honoree and Sparkle of Hope Award Presentation Will Lewis
We extend our heartfelt thanks to Fred & Noreen Hassan and Brent Saunders
Chair and CEO, Insmed Sparkle of Hope Honoree
Closing Remarks Brent Saunders
for embodying Community Hope’s Mission. Your unwavering dedication and support of the
Networking and Cash Bar (cash bar excludes beer & wine) Dessert Buffet
7:40pm
Sparkle of Hope Gala are truly appreciated!
Silent Auction Closes Winners proceed to Auction Payment, 2nd Floor Wine Pull Pick up your bottle at exit, 1st Floor Coffee & light snacks to go at Exit Grand Foyer
8:30pm
9:00pm
Thank you for supporting Community Hope’s mission!
Sparkle of Hope Honoree
Sparkle of Hope Leadership Chair
WILLIAM H. LEWIS, J.D., M.B.A. Chair and CEO Insmed
BRENTON L. SAUNDERS CEO and Chairman Bausch+Lomb Corporation
Will joined Insmed in 2012 as President and Chief Executive Officer and as a member of the board of directors. He became Chair of the Board of Directors in November 2018. Will is the former Co-Founder, President, and Chief Financial Officer of Aegerion Pharmaceuticals, Inc. (Nasdaq: AEGR), and previously spent more than 10 years working in investment banking in the U.S. and Europe. He also previously worked for the U.S. government. Will holds a Bachelor of Arts degree cum laude from Oberlin College as well as a Master of Business Administration and a Juris Doctor with Honors from Case Western Reserve University. Will is the Chair of the board of directors of NewAmsterdam Pharma (Nasdaq: NAMS).
Brent Saunders is a proven leader with more than 25 years of experience across the health care sector. He has served in senior executive roles at several global pharmaceutical and health care companies, where he has successfully overseen numerous value-enhancing initiatives, transactions and integrations. He rejoined Bausch + Lomb as Chief Executive Officer and
Chairman of the Board of Directors in March 2023. Mr. Saunders initially served as CEO from 2010 until 2013, when the company was acquired by Bausch Health Companies Inc. (then known as Valeant Pharmaceuticals, Inc.). Mr. Saunders previously co-founded and served as Chairman of the Board of Vesper Healthcare Acquisitions Corp. Prior to that, he was Chairman, President and CEO of Allergan plc. until the company’s $63 billion acquisition by AbbVie Inc in 2020. Before that, he was President and CEO and a director of Forest Laboratories Inc., until that company’s $25 billion merger with Actavis plc. in 2014, when he was named CEO of the combined business. He then successfully led Actavis’ $66 billion acquisition of Allergan. Mr. Saunders’ first role as an executive officer in the pharmaceuticals and health care space was as a member of the executive management team at Schering-Plough Corporation. While there, he led the integration of Organon Biosciences N.V., after Organon was acquired by Schering-Plough, as well as the merger between Schering-Plough and Merck & Co., Inc. Earlier in his career, Mr. Saunders was a Partner and Head of Compliance Business Advisory at PricewaterhouseCoopers LLP. Prior to that, he was Chief Risk Officer at Coventry Health Care, Inc., Senior Vice President of Compliance, Legal and Regulatory at Home Care Corporation of America, and Chief Compliance Officer for the Thomas Jefferson University Health System. Mr. Saunders currently serves as Chairman of the Board of The Beauty Health Company (Nasdaq: SKIN) and as a director of ARS Pharmaceuticals, Inc. (Nasdaq: SPRY). He is Chairman of the Board of Roam, a director of Cambrian BioPharma and Arena AI, and a Nextech board advisor. His prior board experience includes BridgeBio Pharma, Inc. (Nasdaq: BBIO), Cisco Systems, Inc. (Nasdaq: CSCO), Glo Pharma, OcuTerra Therapeutics and Osmind. He is also a member of the Executive Committee of Mt. Sinai Medical Center. Mr. Saunders holds a B.A. from the University of Pittsburgh, a J.D. from the Temple University School of Law, and an M.B.A. from the Temple University School of Business.
Sparkle of Hope Founding Chair
Sparkle of Hope Honorary Chair
FRED HASSAN Chairman, Caret Group Director, Warburg Pincus
ROB M. DAVIS Chairman and CEO Merck
Rob Davis is chairman of the board and chief executive officer of Merck. Previously, Rob served as Merck’s president, responsible for the company’s operating divisions — Human Health, Animal Health, Manufacturing and Merck Research Laboratories. Prior to that, he was executive vice president, Global Services, and
Fred Hassan is a Director with the private equity firm, Warburg Pincus. He is also a Board member of BridgeBio, EyePoint, Precigen, and Cocrystal Pharma. Fred Hassan is the former Chairman and CEO of Schering-Plough Corporation. Prior to joining Schering-Plough in April 2003, Hassan was Chairman and CEO of Pharmacia Corporation – a company that was formed in March 2000 from the merger of Monsanto and Pharmacia & Upjohn. Hassan joined Pharmacia & Upjohn as CEO in 1997. Previously, Hassan was EVP of Wyeth, with responsibility for its global pharmaceutical and medical products businesses. He was elected to Wyeth’s Board in 1995. Earlier in his career, Hassan spent 17 years with Sandoz Pharmaceuticals (now Novartis) and became CEO of its US division. Hassan received a B.S. degree in chemical engineering from the Imperial College of Science and Technology at the University of London and an M.B.A. from Harvard. Hassan is a founder or co-founder of three major events every year where the bioscience industry is well represented. These are: the CEOs Forum (since 2013), RDL (Research and Development Leadership Summit) (since 2012), and Sparkle of Hope (since 1998). In 2014, a CNBC panel named Hassan to a list of those who have had the most profound impact on the world of business in the previous quarter century
the company’s chief financial officer. Rob joined the company as chief financial officer in 2014 with additional responsibility for real estate operations, corporate strategy and business development. In 2016, his role was expanded to include responsibility for information technology and procurement, forming Global Services. He became president in April 2021, CEO and a member of the board of directors on July 1, 2021, and chairman of the board on December 1, 2022. Prior to joining Merck, Rob was corporate vice president and president of Baxter’s medical products business. During his tenure at Baxter, he held several other positions, including president of Baxter’s renal business, chief financial officer and treasurer. Before joining Baxter in 2004, Rob held numerous positions of increasing responsibility over 14 years at Eli Lilly and Company. Rob serves on the board of directors for Duke Energy Corporation, one of America’s largest energy holding companies, and is chair of its finance and risk management committee and a member of the corporate governance committee. In addition, Rob is a member of the Northwestern Law Board at the Northwestern University Pritzker School of Law. He is also a board member of Project HOPE, a nonprofit organization focused on empowering health care workers to deliver expert care when and where it is needed most, and of Catalyst, a global nonprofit that promotes equal access to career opportunities and corporate leadership for women. Rob received his J.D. from the Northwestern University Pritzker School of Law, his M.B.A. from Northwestern University’s Kellogg Graduate School of Management and his bachelor’s degree in finance from Miami University.
Sparkle of Hope Gala Chair OLIVIER BOGILLOT Head North America General Medicines Sanofi
Sparkle of Hope Gala Chair
ROBERT A. BRADWAY Chairman and CEO Amgen
Robert A. Bradway is Amgen’s chairman and chief executive officer. He became chairman in January 2013 and chief executive officer in May 2012. Bradway served as the
As Head of North America General Medicines, Olivier Bogillot leads the business unit responsible for serving the Diabetes, Transplant and Established Products communities.
company’s president and chief operating officer from May 2010 to May 2012, and was appointed to the Amgen Board of Directors in October 2011. He joined the company in 2006 as vice president, Operations Strategy, and served as executive vice president and chief financial officer from April 2007 to May 2010. Prior to joining Amgen, Bradway was a managing director at Morgan Stanley in London where, beginning in 2001, he had responsibility for the firm’s banking department and corporate finance activities in Europe. He joined Morgan Stanley in New York as a health care industry investment banker in 1985 and moved to London in 1990. Bradway is a member of the board of directors of The Boeing Company, chairing its Governance and Public Policy Committee and serving on its Compensation Committee. He also serves as a board member of the W. M. Keck Foundation and the Pharmaceutical Research and Manufacturers of America. Bradway also serves on the board of trustees of the University of Southern California, he is an Emeritus Director of the CEO Roundtable on Cancer, and he is a member of the American Heart Association CEO Roundtable. Bradway holds a bachelor’s degree in biology from Amherst College and a master’s degree in business administration from Harvard University.
Prior to this role, Olivier was the President of Sanofi France where he led the Strategic Committee and the Country Council of Sanofi France, coordinating all the activities of the French subsidiary and representing the Group to French Authorities and professional organizations. He joined Sanofi in 2015, and has held various positions within the company, including as Executive Director of Global Policy based in the U.S. and Chief of Staff to the CEO. Olivier held key roles in market access at Merck KGaA, Amgen and Bristol-Myers Squibb before being appointed Chief of Staff to the Director at the Greater Paris Regional Health Agency in 2009. He subsequently joined the Presidency of the French Republic in 2011, as advisor for health, dependency, and social policies. He holds a PhD in Economics from the University of Lyon I, a master’s degree in Health Economics and Public Health, and a degree in Molecular Biology and Physiology. He sits on the Board of Directors of Les Entreprises du Médicament (Leem), the Board of Directors of Clariane (CLARI), and chairs the French Federation of Health Industries (FEFIS).
A DELE M. G ULFO
Sparkle of Hope Gala Chair
Sparkle of Hope Gala Chair
VICTOR BULTO President, Novartis US Novartis Pharmaceuticals
ADELE M. GULFO Global President/Board Director Healthcare Sector President & CEO Biopharma Strategies & Insight Adele is a globally recognized healthcare executive, known for industry-leading clinical development and commercialization of the world’s most successful medicines at Pfizer, AstraZeneca, Viatris and Sumitomo Pharma. She most recently served as Chief Executive Officer, A dele is a globally recognized healthcare executive, known for industry-leading clinical development and commercialization of several of the world’s most successful medicines at Pfizer, AstraZeneca, and Sumitomo Pharma. She most recently served as the Chief Executive Officer, Biopharma Commercial Unit, for Sumitomo Pharma America, Inc. where she had oversight of the Company’s commercial and development portfolio of $1.2B+ across multiple therapeutic areas including, oncology, rare, urology, CNS and Women’s Health. Biopharma Commercial Unit, for Sumitomo Pharma America, Inc. [TSE:4506] where she led the organization to 46% revenue growth and delivered significant profit improvement across a diverse portfolio spanning oncology, rare disease, urology, neurology and women’s health. Ms. Gulfo previously served as Country Manager for Pfizer’s US biopharmaceutical businesses, including Specialty, Oncology, and Vaccines, which generated over $20B during her tenure. She was Pfizer’s President of Latin America ($4B business), where she led a team of over 4,000 colleagues across 24 countries and was President of Pfizer’s $12B+ US primary care business unit, comprised of over 5,000 employees across multiple therapeutic areas. Ms. Gulfo was Executive Vice President, Chief Strategy Officer, and Head of Global Commercial Development at Mylan, which is now Viatris Prior to joining Pfizer, she spent 9 years at AstraZeneca where she held executive roles in General Management, and Business Development. She ran the company’s Cardiovascular business unit where she led the successful launch of CRESTOR® (peak sales $6.6B) and secured a transformative partnership in diabetes. Before joining AstraZeneca, Ms. Gulfo planned and executed the commercial launch for LIPITOR®, the world’s most successful branded medicine with more than $125B in global sales over ~14.5 years. Prior to her time at Pfizer, Ms. Gulfo spent nine years at AstraZeneca where she held executive P&L roles in General Management and Business Development. She led the company’s Cardiovascular business unit spearheading the successful launch of CRESTOR® (peak sales $6.6B) and securing a transformative diabetes partnership with BMS. Earlier in her career, Ms. Gulfo planned and executed the commercial launch for LIPITOR®, the world’s most successful branded medicine, which achieved peak U.S. sales exceeding $13B. Ms. Gulfo previously served as Country Manager for Pfizer’s U.S. biopharmaceutical businesses, including Specialty, Oncology, and Vaccines, which generated over $20B during her tenure. She also served as President of Latin America, leading a $4B business with more than 4,000 colleagues across 24 countries, and as President and General Manager of Pfizer’s $12B+ U.S. primary care business unit, managing 5,000+ employees across multiple therapeutic areas. She later served as Executive Vice President, Chief Strategy Officer, and Head of Global Commercial Development at Viatris. E XECUT I VE B IO Adele is a globally recognized healthcare executive, known for industry-l commercialization of the world’s most successful medicines at Pfizer, Ast Pharma. She most recently served as Chief Executive Officer, Biopharma Commer America, Inc. [TSE:4506] where she led the organization to 46% revenue profit improvement across a diverse portfolio spanning oncology, rare women’s health. Adele has extensive public company board experience and has served on committees including Audit, Nominating and Governance, Compensation, and Investment. She currently serves as a director on EnPro Industries [NYSE: NPO], a leading industrial engineering firm that designs, develops and manufactures proprietary engineered products for use in markets such as semiconductor, nuclear, food, pharma and aerospace. From 2019 to 2023, she served on the board of Myovant [NYSE: MYOV] a company focused on Women’s Health and Prostate Cancer, which was acquired by Sumitomo Pharma in 2023. She served on the board of Bemis Company [NYSE: BMS] a global supplier of industrial packaging for five years, which merged with Amcor in 2019. She served on Medexus [TSX:MDP] for five years and currently serves on the Innovation Growth Board for Mass General Brigham, the largest hospital-based research enterprise in the US, with annual funding of more than $2B. Trained as a scientist, she has been awarded six U.S. patents on novel medication packaging and allergy treatments. She holds a Bachelor of Science degree in biology from Seton Hall University; an MBA with highest honors from Fairleigh Dickinson University; and studied post- graduate Molecular Biology and began her career at the University of Medicine and Dentistry of New Jersey (now Rutgers School of Biomedical Sciences). Ms. Gulfo has extensive public company board experience, having served on various committees, including Audit, Nominating and Governance, Compensation, and Investment. She currently serves on Enpro [NYSE:NPO], a leading industrial engineering firm that designs, develops, and manufactures proprietary engineered products for use in semiconductor, nuclear, pharma, and aerospace. She also serves on the boards of New Amsterdam Pharma [NASDAQ: NAMS], which focuses on cardiovascular disease and Tyra Biosciences [NASDAQ: TYRA], which specializes in oncology and rare disease. Previously, she served on Myovant [NYSE: MYOV], which was acquired by Sumitomo Pharma. She also served on the board of Bemis Company [NYSE: BMS] a global supplier of industrial and healthcare packaging until its acquisition by Amcor [NYSE: AMCR]. She served on Medexus [TSX:MDP] a Biopharma company with a portfolio across allergy, dermatology, hematology and rheumatology. She currently serves on the Innovation Growth Board for Mass General Brigham, the largest U.S. hospital-based research enterprise in with $2B+ in annual funding. Trained as a scientist, Ms. Gulfo has six U.S. patents. She earned a Bachelor of Science degree in Biology from Seton Hall University, an MBA with highest honors from Fairleigh Dickinson University, pursued post-graduate studies in Molecular Biology and began her career at the Rutgers School of Biomedical Sciences. Ms. Gulfo previously served as Country Manager for Pfizer’s U.S. biophar Specialty, Oncology, and Vaccines, which generated over $20B during President of Latin America, leading a $4B business with more than 4,000 co as President and General Manager of Pfizer’s $12B+ U.S. primary care employees across multiple therapeutic areas. She later served as Executiv Officer, and Head of Global Commercial Development at Viatris. Global President / − Healthcare Enterprise Strategy Leadership Board Experience □ Stra Global Markets □ Ta
Victor Bulto is President of Novartis US and reports to Novartis CEO Vas Narasimhan. As the US President, Victor is pursuing a bold strategy to reimagine medicine and deliver on the company’s responsibility to unlock the potential for helping patients in the world’s largest healthcare market. Prior to this role, Victor served as President, Novartis
Pharmaceuticals Corporation, leading the US pharmaceuticals business. He has been with Novartis for over 20 years and has broad, multi-national experience in the healthcare industry. He has worked across every therapeutic area at Novartis Pharmaceuticals and played critical roles in launching numerous products. He held various other positions at Novartis, including Head of the US Alcon Pharmaceuticals Franchise and Head of the Neuroscience Franchise for Region Europe, where he had responsibility for the overall strategy, growth and profitability of these businesses. Before joining Novartis, Victor was a medical device sales representative. Victor is driven by the pressing need to translate medicines to outcomes for broad patient populations and transform the patient experience to help mitigate the challenges people living with disease face in getting diagnosed, obtaining medicine, and staying on treatment within the complex US healthcare system. He has a strong track-record as a people-first leader with a focus on creating a culture where each individual can show up every day as their authentic self to best serve the interests of people living with disease. A lifelong learner, Victor has a master’s degree in Health Economics and Pharmaeconomics and a postgraduate degree in Pharmaceutical Marketing from Universitat Pompeu Fabra. He also received his Master’s in Business Administration from Esade. In 2019, Victor attended the Harvard Business School Advanced Management Program, Business Administration and Management, and from 2007-2008 he attended the postgraduate certificate program in leadership at Glasgow Caledonian University. Victor also holds a master’s degree in Chemical Engineering and a Bachelor of Science in Chemistry from the Institut Químic de Sarrià.
Sparkle of Hope Gala Chair
Sparkle of Hope Gala Chair
CHRISTOPHER HITE Vice Chairman Royalty Pharma
ANNA KAZANCHYAN Founder and CEO Saghmos Therapeutics
Chris has over 25 years of experience advising biopharmaceutical companies on mergers and acquisitions and capital formation. Prior to joining Royalty Pharma in 2020, Chris was an investment banker at Citi where he was the Global Head of Healthcare for nearly 12 years and most recently a vice chairman of Banking,
Anna Kazanchyan, M.D., is CEO and Founder of Saghmos Therapeutics and has over 25 years of experience at marquee Wall Street firms, biopharmaceutical companies and as an entrepreneur. She has a unique combination of equity research, business and clinical strategy as well as business development experience and expertise. Dr.
Capital Markets and Advisory (“BCMA”) and also sat on the Executive Committee of BCMA. Prior to joining Citi, Chris was the Global Head of Healthcare Investment Banking at Lehman Brothers. Chris serves on the Board of Trustees at Lehigh University, the Board of Advisors of Faster Cures, a center of the Milken Institute, the Board of Directors of Kailera Therapeutics and served on the Board of Directors of Acceleron Pharma Inc. (Nasdaq: XLRN) until its acquisition by Merck in November 2021 for $11.5 billion. Chris has a BS from Lehigh University and a JD and MBA from the University of Pittsburgh.
Kazanchyan has served as a member of the Board of Directors for several publicly traded biopharmaceutical companies and as a Coach for the WomenInBio’s BoardRoom Ready initiative. She was previously Managing Partner of Primary i-Research, where she provided due diligence to leading multi-billion dollar healthcare investment funds and evaluated investment prospects of hundreds of biopharma companies based on the scientific, clinical, regulatory, and commercial outlook for their products. In addition, Dr. Kazanchyan was retained as an Executive Advisor by CEOs and Boards of global biopharmaceutical companies on matters of high strategic importance related to business development, competitive intelligence, regulatory strategy, marketing and commercial/competitive landscape. Previously, she was SVP, Business Development and Product Development at Ovid Therapeutics. Dr. Kazanchyan was also Senior Biotechnology Analyst at Wells Fargo Securities and was a member of the #1 and #2 Institutional-Investor ranked Biotechnology Equity Research teams at Goldman Sachs and Citigroup, respectively. She received an M.D. from Harvard Medical School and a B.A. in Biology, summa cum laude, from Clark University.
Sparkle of Hope Gala Chair KEVIN LOBO Chair and CEO Stryker
Sparkle of Hope Gala Chair MARK MCKENNA Chairman and CEO Mirador Therapeutics, Inc.
Mark C. McKenna is the founder, Chairman, and CEO of Mirador Therapeutics, and a renowned biotech entrepreneur, executive, and director known for his exceptional leadership and visionary approach. Mirador is a next-generation precision medicine company focused on developing first-in-class or best-in- class precision medicines for immunology and inflammation. Launched in 2024, Mirador has raised over $400 million plus
Kevin is Chair and Chief Executive Officer of Stryker, one of the world’s leading medical technology companies. Appointed CEO in October 2012 and Chair of the Board in July 2014, Kevin joined Stryker in 2011 and previously served as Group President of Orthopaedics. Under his leadership, Stryker has completed more than 60 acquisitions and advanced innovation and global market presence.
from leading life sciences investors and is based in San Diego, CA. Prior to Mirador, Mr. McKenna served as Chairman, President, and CEO of Prometheus Biosciences from 2019 until its acquisition by Merck for $10.8 billion in June 2023. Under his leadership, Prometheus raised over $1 billion in private and public financing, was recognized as the top-performing biotech IPO of 2021, and pioneered the first precision therapeutics clinical trial for immune-mediated diseases. This led to its acquisition by Merck, resulting in the largest buyout of company with a pre-Phase 3 asset to date. Prior to Prometheus Mr. McKenna was the President of Salix Pharmaceuticals and a corporate officer at Bausch + Lomb. There, he revitalized the gastroenterology business through strategic acquisitions and product launches, doubling revenue to over $2 billion and significantly enhancing operating margins. He also spent over a decade at Bausch + Lomb, where he was SVP and General Manager of the US Vision Care business. Mr. McKenna began his career at Johnson & Johnson, where he held several positions of increasing responsibility. He currently serves as the Chairman of Apogee Therapeutics, Inc. (Nasdaq: APGE) and is a board member of Spyre Therapeutics, Inc. (Nasdaq: SYRE) and New Amsterdam Pharma (Nasdaq: NAMS). In addition, Mr. McKenna is a Venture Partner at Arch and Senior Advisor to Fairmount Funds. Mr. McKenna holds a B.S. in marketing from Arizona State University and an MBA from Azusa Pacific University. Mr. McKenna also completed the Wharton’s Fellows Program at the University of Pennsylvania School of Business. Mr. McKenna is passionate about solving big problems in medicine and is regularly featured on CNBC’s Mad Money and Bloomberg radio. In addition, Mr. Mckenna is a frequent guest speaker at the Longwood Healthcare Conference and other industry thought leader
A recognized leader in innovation and workplace excellence, Kevin has been named to Forbes’ list of America’s Most Innovative Leaders, received the Ellis Island Medal of Honor (2023), and was honored with a CEO for All Leadership Award from Great Place to Work. During Kevin’s tenure with the company, Stryker’s strong emphasis on people and culture has earned it steady recognition as a Great Place to Work globally and across multiple categories, including the World’s Best Workplaces and the 100 Best Companies to Work For. With a career spanning finance, general management, and healthcare leadership across global markets, Kevin brings a wealth of strategic insight and operational expertise. Prior to Stryker, he held leadership roles at Johnson & Johnson, including President of Ethicon Endo Surgery, President of J&J Medical Products Canada, and CFO roles within its consumer and women’s health divisions. Earlier in his career, he held finance and management roles at Rhone-Poulenc, including assignments in Europe, as well as at Kraft Canada, Unilever, and KPMG. He serves on the Boards of Parker Hannifin (NYSE:PH) and the Advanced Medical Technology Association (AdvaMed) and is a member of the Business Council. Additionally, he serves as Chair of the Valley Health System’s board of trustees in New Jersey. Kevin holds a Bachelor of Commerce from McGill University, an MBA from the University of Toronto, and is a Chartered Accountant.
events. In 2023 he was selected as EY’s Entrepreneur of the year, being recognized for his contributions to advancement of entrepreneurship and science.
Sparkle of Hope Gala Chair
Sparkle of Hope Gala Chair JOSEPH C. PAPA
BILL MEURY President and CEO Incyte Corporation
Chief Executive Officer Emergent BioSolutions
Joseph is an experienced healthcare leader who has spent his career championing products that improve patients’ lives and empowering the teams responsible for bringing those products to market. His track record of driving growth and navigating companies through periods of transformation, make Joseph the right leader to help Emergent deliver on its mission, and potential.
Bill Meury joined Incyte in 2025 as President, Chief Executive Officer (CEO) and a member of the Company’s Board of Directors. With over three decades of industry experience, Mr. Meury is a proven enterprise leader with expertise in organizational strategy, pipeline and commercial execution and capital allocation.
Prior to joining Incyte, Mr. Meury was CEO of Anthos, where he successfully scaled the company for its next stage of growth. Before joining Anthos Therapeutics, Mr. Meury served as President and CEO of Karuna Therapeutics, leading its transition into a fully integrated R&D and commercial organization. Prior to Karuna, he served as a Partner at Hildred Capital Management, a private equity firm focusing on healthcare products and services. Earlier in his career, Mr. Meury spent more than two decades at Allergan, serving as Chief Commercial Officer, managing a global business with fifty products, $16 billion in revenue and approximately 8,000 employees across a range of therapeutic areas. He also served as Allergan’s President, Branded Pharma and Executive Vice President, Commercial, North American Brands, and as Executive Vice President Commercial Operations at Forest Laboratories prior to its acquisition by Allergan. Mr. Meury has experience across a broad range of therapeutics areas and has been involved with over 20 U.S. FDA approvals and new product launches, as well as 25 different BD&L transactions. He received his Bachelor of Arts degree in Economics from the University of Maryland and currently serves on the board of The Jed Foundation.
Joseph brings over 35 years of experience in the healthcare and pharmaceutical industry, having most recently served as chief executive officer and chairman at Bausch and Lomb Corporation, a global eye health company. Prior to his role at Bausch and Lomb, he was the chief executive officer and chairman of Bausch Health, now Bausch Health Companies Inc. He also served as chairman and CEO of Perrigo, and held leadership positions at Cardinal Health, Watson Pharmaceuticals, and Novartis. He currently is the chairman of the board of SparingVision, a privately held genomic medicines company, and is a member of the board of directors of Candel Therapeutics.
Sparkle of Hope Gala Chair
Sparkle of Hope Gala Chair
TAREK RABAH Chief Executive Officer Otsuka America, Inc.
BRENT RAGANS President Ferring Holding Inc. (US)
Throughout his career, Tarek has brought together high- functioning teams that challenge conventional thinking and deliver results in complex, challenging business environments. His commitment to empowering and supporting those around him has unlocked innovation and directly impacted the lives of patients. As a citizen of the world, Tarek brings an intuitive global perspective that infuses diversity, transparency, and performance accountability as key tenets in his business philosophy. Tarek is a growth-oriented executive with extensive experience leading large, multifaceted commercial organizations. In his more than 20 years of experience, he has successfully launched brands and led divisions with AstraZeneca and Novartis in the United States, Europe, South America, Japan, and the Middle East. His expertise spans therapeutic areas in highly competitive and complex healthcare categories. For Tarek, leadership is not about having all the answers, rather it is about creating an environment where Otsuka-people are deeply connected to their purpose, and the people they serve. Tarek joined Otsuka in 2022 as President & CEO of Otsuka’s North America Pharmaceutical Business, with responsibility in the US and Canada. Driven by his personal passion to improve the lives of people, Tarek is leading Otsuka’s commercial organization efforts to introduce products, programs, policies, and advocacy initiatives that help address unmet medical needs and untapped market opportunities. He holds a BS in Biology and a BA in Business from the American University of Beirut, and an MBA from McGill University. He is fluent in five languages. “We truly work to change lives at Otsuka—I am continuously inspired by Otsuka-people to uncover new ways to advance innovative health solutions, and for the opportunity to make an impact in the lives of those we serve.”
Brent Ragans is the U.S. President of Ferring Pharmaceuticals, a privately-owned, biopharma company that focuses on developing life-changing innovations that help people live better lives. In the United States, Ferring is a leader in reproductive medicine, uro-oncology and in specialty areas within orthopaedics, and gastroenterology, including microbiome therapeutics.
Brent’s vision for serving patients is grounded in Ferring’s 70-year commitment to science, research and the relentless pursuit of therapies that help people build families, stay healthy and fight disease. Becoming president in June 2020, Brent focused Ferring U.S. in the therapy areas where it makes the greatest positive differences for patients. Previously as U.S. Chief Commercial Officer, Brent led commercial strategy and operations as the company introduced new products and doubled its sales. Brent has extensive experience in the pharmaceutical industry, including leading multiple units and teams in both prescription pharmaceuticals and consumer OTC. Before joining Ferring in 2012, he built and led several multibillion-dollar brands for Sanofi, where his last position was Senior Vice President of North American Consumer Healthcare Strategy and Corporate Development. Brent began his career at Bock Pharmaceuticals. Brent holds a Bachelor of Science degree in Legal Communications and Marketing from Florida State University. Outside of Ferring, Brent contributes his efforts to supporting several philanthropic and educational causes. He sits on the Board of Directors for Community Hope and is a Co-Chair for their Sparkle of Hope Gala. Brent is also a Co-Chair of the SDHB PheoPara Coalition Gala. He is a member of the Healthcare Leadership Council based in Washington, DC. Brent is also an active participant in the mentorship program of Florida State University, where he also shares his experience and expertise as a business leader with MBA students as a guest lecturer.
Sparkle of Hope Gala Chair
Community Hope Deeply thanks Our Sponsors and Donors For your support Of our organization through the 29th Annual
ADAM SCHECHTER Chairman, President and CEO Labcorp
Global business leader Adam Schechter became Chief Executive Officer of Labcorp in 2019 and Chairman of the Board in May 2020. Prior to that, he was named Lead Independent Director after serving as a director of the company since 2013. Before joining Labcorp, Mr. Schechter held a variety of senior
leadership positions at Merck & Co., Inc. He was Executive Vice President and President of Merck’s Global Human Health Division from 2010 to 2018 leading the company’s worldwide pharmaceutical and vaccine businesses. In this role, he was also a member of Merck’s executive committee. Prior to becoming President of Merck’s Global Human Health Division, Mr. Schechter served as President of Merck’s global pharmaceutical business from 2007 to 2010. His extensive experience at Merck also included global and U.S.-focused leadership roles spanning sales, marketing and managed markets, as well as business and product development. Mr. Schechter has been a Board Member for DaVita Inc. since 2022, and he serves on the Board for Water.org. He also serves as the American Clinical Laboratory Association (ACLA) Board Vice-Chair, and a member of the Corporate Advisory Council for the National Alliance for Hispanic Health. In 2025, Mr. Schechter joined the Board of Project HOPE, a leading global health and humanitarian organization. Previously, he served on the Boards of the European Federation of Pharmaceutical Industries and Associations (EFPIA), where he led the Policy and Access Committee, the Healthcare Leadership Council and the Merial Animal Health Company. Mr. Schechter holds a Bachelor of Science degree in biology and an honorary Doctorate of Humane Letters degree from La Salle University in Philadelphia, Pennsylvania.
It is our honor to work together in support of our mission!
Event Sponsors
Event Sponsors Patron Sponsor Amneal • Catalent • Catalyst • Citibank • Covington Emergent BioSolutions • Emerson Electric • Gary’s Wine • Goldman Sachs GordonMD Global Investment • Indegene • Jones LaSalle Lazard • Leerink Partners • Mirador Therapeutics Sharon Marcil and Tom Monahan Schwartz Family Foundation • Seed Therapeutics Teneo • Tris Pharma, Inc. • Vinci Pharmaceuticals Supporter Adage Capital Management, L.P. • Axtria • BlinkRx Cheeley Consulting • Cormedix • Enterprise Fleet Management Fingerpaint • Molly & Bill Ford • Harmony Biosciences HarrisonRand • Iannetta Foundation • Johnson & Johnson KMK Consulting • Matthijssen • NJM • Phil Russel Reynolds & Associates • Simtra BioPharma Solutions Spencer Savings • The Westfield Group • Trinity Life Sciences Venable • Warbur Pincus • Withum Contributors Barshay • Paul Boudreaus & Associates LLC • Brown & Brown BSI • Richard Chera • The Conference Forum
Community Hope would like to thank our 2025 Sparkle of Hope Sponsors.
You gave so generously to our organization in support of our mission and realize our work helping homeless veterans, veteran families and adults with mental illness is critical. We are so thankful for your generosity! Premier Sponsor Accenture • Bank of America • Bristol Myers Squibb Centerview Partners LLC • Insmed • JP Morgan Klick • Merck • Royalty Pharma Verizon • Wachtell, Lipton, Rosen & Katz Presenting Sponsor Bausch + Lomb • Davis Polk Ferring Pharmaceuticals • Fred Hassan & Noreen Hassan Incyte Corporation • Knipper Health • Otsuka Pfizer • Pharmakon Advisors LP PWC/Pricewaterhouse Cooper • Saghmos Therapeuetics, Inc. Sanofi • Stryker • Thermo Fisher Scientific • Veeva Systems Benefactor Sponsor Amgen • Ariel Investment • Bausch Health BCG • BD • Eyepoint Pharmaceuticals GoodRx • IQVIA • LabCorp
Dr. Stephen Mayo • Sage Broadview • Mark Schaffer To all those whose names we were unable to list due to publication deadlines, please know your contributions are very much appreciated!
Lowenstein Sandler • McKinsey & Company Morgan Stanley • New Amsterdam Pharma Novartis • Northrop Grumman
Page 1 Page 2-3 Page 4-5 Page 6-7 Page 8-9 Page 10-11 Page 12-13 Page 14-15 Page 16-17 Page 18-19 Page 20-21 Page 22-23 Page 24-25 Page 26-27 Page 28-29 Page 30-31 Page 32-33 Page 34-35 Page 36-37 Page 38-39 Page 40-41 Page 42-43 Page 44-45 Page 46-47 Page 48-49 Page 50-51 Page 52-53 Page 54-55 Page 56-57 Page 58-59 Page 60-61 Page 62-63 Page 64-65 Page 66-67 Page 68-69 Page 70-71 Page 72-73 Page 74-75 Page 76-77 Page 78-79 Page 80-81 Page 82-83 Page 84-85 Page 86-87 Page 88-89 Page 90-91 Page 92-93 Page 94Made with FlippingBook - Online Brochure Maker